1. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.
Ann Surg Oncol. Jan–Feb 2001;8(1):50–59.
[PubMed: 11206225]
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
Ann Surg. 2000;231(1):51–58.
[PubMed: 10636102]
3. Lewis JJ, Brennan MF. Soft tissue sarcomas.
Curr Probl Surg. 1996; 33(10):817–872.
[PubMed: 8885853]
4. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000 Oct; 15(4):1293–1301.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.
Virchows Arch. 2001;438(1):1–12.
[PubMed: 11213830]
6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005 Feb 15;103(4):821–829.
7. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983 Sep;7(6):507–519.
8. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.
Am J Pathol. 1998;152(5):1259–1269.
[PubMed: 9588894]
9. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002 Sep;38(suppl 5):S39–S51.
10. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 23 1998 Jan 23;279(5350):577–580.
11. Savage DG, Antman KH.
Imatinib mesylate—a new oral targeted therapy.
N Engl J Med. 2002 Feb 28;346(9):683–693.
12. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15;61(22):8118–8121.
13. Tian Q, Frierson HF, Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors.
Am J Pathol. 1999;154(6): 1643–1647.
[PubMed: 10362788]
14. Ward SM, Burns AJ, Torihashi S, Sanders KM. Mutation of the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. J Physiol. 1994 Oct 1;480 (pt 1):91–97.
15. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach.
Hum Pathol. 2002;33(5):459–465.
[PubMed: 12094370]
16. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002 Mar 15;20(6):1692–1703.
17. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors.
J Clin Oncol. 2004;22(18):3813–3825.
[PubMed: 15365079]
18. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and
imatinib response in patients with metastatic gastrointestinal stromal tumor.
J Clin Oncol. 2003 Dec 1;21(23):4342–4349.
19. De Giorgi U, Verweij J.
Imatinib and gastrointestinal stromal tumors: where do we go from here?
Mol Cancer Ther. 2005;4(3):495–501.
20. Emile JF, Theou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.
Clin Gastroenterol Hepatol. 2004;2(7):597–605.
[PubMed: 15224284]
21. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31;299(5607): 708–710.
22. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003 Sep;125(3):660–667.
23. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
Am J Surg Pathol. 2004;28(7):889–894.
[PubMed: 15223958]
24. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to
imatinib.
J Clin Oncol. 2005 Aug 10;23(23):5357–5364.
25. Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008 May 15;14(10):3204–3215.
26. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387–8392.
27. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.
Pol J Pathol. 2003;54(1):3–24.
[PubMed: 12817876]
28. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence.
Mayo Clin Proc. 1999;74(6):543–552.
[PubMed: 10377927]
29. Beghini A, Tibiletti MG, Roversi G, et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer. 2001 Aug 1;92(3):657–662.
30. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002 Mar 1;108(2):132–139.
31. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.
Gastroenterology. 2002;122(5):1493–1499.
[PubMed: 11984533]
32. Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol. 2000 Nov;157(5):1581–1585.
33. Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005 Apr 20;23(12):2735–2743.
34. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene.
Gastroenterology. 2001;120(1):210–215.
[PubMed: 11208730]
35. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet. 1998 Aug;19(4):323–324.
36. Robson ME, Glogowski E, Sommer G, et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res. 2004 Feb 15;10(4):1250–1254.
37. Chompret A, Kannengiesser C, Barrois M, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.
Gastroenterology. 2004;126(1):318–321.
[PubMed: 14699510]
38. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004 Sep 15;22(18):3813–3825.
39. Shinomura Y, Kinoshita K, Tsutsui S, Hirota S. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors.
J Gastroenterol. 2005;40(8):775–780.
[PubMed: 16143881]
40. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.
Am J Surg Pathol. 2006;30(1):90–96.
[PubMed: 16330947]
41. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997 Jun 1;79(11):2125–2131.
42. Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease).
Am J Surg Pathol. 2005;29(6):755–763.
[PubMed: 15897742]
43. Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients.
J Pathol. 2004;202(1):80–85.
[PubMed: 14694524]
44. Carney JA, Sheps SG, Go VL, Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med. 1977 Jun 30;296(26):1517–1518.
45. McWhinney SR, Pasini B, Stratakis CA. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med. 2007 Sep 6;357(10):1054–1056.
46. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
J Am Coll Surg. 2006;202(4):623–629.
[PubMed: 16571433]
47. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul;5(suppl 2):S1–S29; quiz S30.
48. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990–2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005 Nov 1;117(2):289–293.
49. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site.
Am J Surg Pathol. 1999;23(1):82–87.
[PubMed: 9888707]
50. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases.
Am J Surg Pathol. 1999;23(9):1109–1118.
[PubMed: 10478672]
51. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.
Am J Surg Pathol. 2000;24(2):211–222.
[PubMed: 10680889]
52. Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases.
Am J Surg Pathol. 2001;25(11):1433–1437.
[PubMed: 11684962]
53. Lasota J, Carlson JA, Miettinen M. Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor.
Arch Pathol Lab Med. 2000;124(6):894–897.
[PubMed: 10835530]
54. Peerlinck ID, Irvin TT, Sarsfield PT, Harington JM. GIST (gastro-intestinal stromal tumour) of the gallbladder: a case report. Acta Chir Belg. 2004 Feb;104(1):107–109.
55. Takahashi Y, Noguchi T, Takeno S, Uchida Y, Shimoda H, Yokoyama S. Gastrointestinal stromal tumor of the duodenal ampulla: report of a case.
Surg Today. 2001;31(8):722–726.
[PubMed: 11510612]
56. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(suppl 5): S37–S38.
57. Bertulli R, Fumagalli E, Coco P, et al. Unusual metastatic sites in GIST [abstr 10566]. J Clin Oncol. 2009;27:15s.
58. Demetri GD, Delaney T. NCCN: sarcoma. Cancer Control. Nov–Dec 2001;8(6 suppl 2):94–101.
59. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO.
Ann Oncol. 2005;16(4):566–578.
[PubMed: 15781488]
60. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of
imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med. 2002 Aug 15;347(7):472–480.
61. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
J Nucl Med. 2004;45(1):17–21.
[PubMed: 14734662]
63. Rader AE, Avery A, Wait CL, McGreevey LS, Faigel D, Heinrich MC. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit.
Cancer. 2001;93(4):269–275.
[PubMed: 11507701]
64. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006 May;23(2):70–83.
65. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008 Feb 1;112(3):608–615.
66. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study.
Hum Pathol. 1998;29(8):791–800.
[PubMed: 9712419]
67. Cooper PN, Quirke P, Hardy GJ, Dixon MF. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract.
Am J Surg Pathol. 1992;16(2):163–170.
[PubMed: 1733349]
68. Gunther T, Schneider-Stock R, Hackel C, et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas.
Clin Cancer Res. 2000;6(5):1811–1818.
[PubMed: 10815902]
69. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging.
Ann Surg. 1992;215(1):68–77.
[PubMed: 1731651]
70. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005 Sep 1;23(25):6190–6198.
71. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients.
Gastric Cancer. 2003;6(1):39–48.
[PubMed: 12673425]
72. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.
Am J Surg Pathol. 2007;31(1):113–120.
[PubMed: 17197927]
73. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach.
Hum Pathol. 2006; 37(12):1527–1535.
[PubMed: 16996566]
74. Davila RE, Faigelm DO. GI stromal tumors.
Gastrointest Endosc. 2003;58(1):80–88.
[PubMed: 12838226]
75. Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases.
Surgery. 2006;139(4):484–492.
[PubMed: 16627057]
76. Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors.
Ann Surg. 2006;243(6):738–745; discussion 745–737.
[PubMed: 16772777]
77. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992 Mar 15;69(6):1334–1341.
78. Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST).
Scand J Surg. 2003;92(3):195–199.
[PubMed: 14582540]
79. Carboni F, Carlini M, Scardamaglia F, et al. Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience. J Exp Clin Cancer Res. 2003 Sep;22(3):379–384.
80. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours.
Br J Surg. 2003;90(3):332–339.
[PubMed: 12594669]
81. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors.
Arch Surg. 2001;136(4):383–389.
[PubMed: 11296107]
82. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the
imatinib (STI-571) era.
Surgery. Oct 2003;134(4):656–665; discussion 665–656.
[PubMed: 14605627]
83. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031–1037.
84. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med. 1996;2(5):561–566.
[PubMed: 8616716]
85. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925–932.
86. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing
imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol. 2008 Feb 1;26(4):626–632.
87. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose
imatinib: randomised trial.
Lancet. 2004 Sep 25–Oct 1;364(9440):1127–1134.
88. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant
imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
J Surg Oncol. 2008 Oct 21;99(1):42–47.
89. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative
imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
Ann Surg Oncol. 2009;16(4):910–919.
[PubMed: 18953611]
90. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose
imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
J Clin Oncol. 2008 Feb 1;26(4):620–625.
91. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours.
Lancet Oncol. 2002;3(11):655–664.
[PubMed: 12424067]
92. DeMatteo R, Owzar K, Antonescu C, et al. Efficacy of adjuvant
imatinib mesylate following complete resection of localized, primary GIST at high risk of recurrence: U.S. intergroup phase II trial ACOSOG Z9000.
ASCO Gastrointestinal Symposium. January 2008.
93. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant
imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Lancet. 2009 Mar 28;373(9669):1097–1104.
94. Zhan WH, Group CGC. Efficacy and safety of adjuvant post-surgical therapy with
imatinib in patients with high risk of relapsing GIST [abstr 10045].
Proc Am Soc Clin Oncol. 2007;25.
95. Kang Y, Kang B, Ryu M, et al. A phase II study of
imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with c-kit exon 11 mutation [abstr 95].
ASCO Gastrointestinal Symposium. 2009.
96. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of
imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Lancet. 2001 Oct 27;358(9291):1421–1423.
97. Raut CP, Hornick JL, Bertagnolli MM. Advanced gastrointestinal stromal tumor: potential benefits of aggressive surgery combined with targeted tyrosine kinase inhibitor therapy. Am J Hematol/Oncol. 2006;5(12):707–712.
98. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with
imatinib: a centre-based study of 17 patients.
Br J Cancer. 2003;89:460–464.
[PubMed: 12888812]
99. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with
imatinib mesylate?
Am J Surg. 2003 Dec;186(6):665–669.
100. Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with
imatinib.
Int J Cancer. 2005 Nov 1;117(2):316–325.
101. (MetaGIST) GSTM-AG. Comparison of two doses of
imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
J Clin Oncol. 2010 Mar 1;28(7):1247–1253.
102. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of
imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
J Clin Oncol. 2007 Mar 20;25(9):1107–1113.
103. Adenis A, Cassier PA, Bui BN, et al. Does interruption of
imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial?
J Clin Oncol. 2008;26:A10522.
104. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of
sunitinib in patients with advanced gastrointestinal stromal tumour after failure of
imatinib: a randomised controlled trial.
Lancet. 2006 Oct 14;368(9544):1329–1338.
105. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of
sunitinib malate in patients with advanced gastrointestinal stromal tumour after
imatinib failure.
Eur J Cancer. 2009 Jul;45(11):1959–1968.
106. Wiebe L, Kasza K, Maki RG, et al.
Sorafenib is active in patients with imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstr 10502].
J Clin Oncol. 2008;26:553s.
107. Blay JY, Casali PG, Reichardt P, et al. A phase I study of
nilotinib alone and in combination with
imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update [abstr 10553].
J Clin Oncol. 2008;26.
108. Bui BN, Blay JY, Duffaud F, Hermine O, Le Cesne A. Preliminary efficacy and safety results of masitinib, front line in patients with advanced GIST. A phase II study [abstr 10025]. J Clin Oncol. 2007;25.
109. Joensuu H, De Braud F, Coco P, et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to
imatinib mesylate.
Ann Oncol. 2008;19(1):173–177.
[PubMed: 17698976]
110. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006 Sep 15;66(18):9153–9161.
111. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.
Ann Surg. 2007;245(3):347–352.
[PubMed: 17435539]
112. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20;24(15):2325–2331.
113. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with
imatinib.
Ann Surg Oncol. 2007;14(1):14–24.
[PubMed: 17072676]
114. Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the
imatinib era.
Ann Surg Oncol. 2006;13(12):1596–1603.
[PubMed: 16957966]
115. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with
imatinib mesylate in advanced/metastatic GIST.
Ann Surg. 2007;245(3):341–346.
[PubMed: 17435538]
116. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with
imatinib mesylate.
J Surg Oncol. 2006 Mar 15;93(4):304–311.
117. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with
imatinib.
Ann Surg Oncol. 2007;14(1):14–24.
[PubMed: 17072676]